title: A1 adenosine receptor-mediated GIRK channels contribute to the resting conductance of CA1 neurons in the dorsal hippocampus.
abstract: The dorsal and ventral hippocampi are functionally and anatomically distinct. Recently, we reported that dorsal Cornu Ammonis area 1 (CA1) neurons have a more hyperpolarized resting membrane potential and a lower input resistance and fire fewer action potentials for a given current injection than ventral CA1 neurons. Differences in the hyperpolarization-activated cyclic nucleotide-gated cation conductance between dorsal and ventral neurons have been reported, but these differences cannot fully account for the different resting properties of these neurons. Here, we show that coupling of A1 adenosine receptors (A1ARs) to G-protein-coupled inwardly rectifying potassium (GIRK) conductance contributes to the intrinsic membrane properties of dorsal CA1 neurons but not ventral CA1 neurons. The block of GIRKs with either barium or the more specific blocker Tertiapin-Q revealed that there is more resting GIRK conductance in dorsal CA1 neurons compared with ventral CA1 neurons. We found that the higher resting GIRK conductance in dorsal CA1 neurons was mediated by tonic A1AR activation. These results demonstrate that the different resting membrane properties between dorsal and ventral CA1 neurons are due, in part, to higher A1AR-mediated GIRK activity in dorsal CA1 neurons.
authors: Department of Neuroscience and Center for Learning and Memory, University of Texas at Austin, Austin, Texas.
authors: Chung Sub
authors: CS
authors: Kim
authors: Department of Neuroscience and Center for Learning and Memory, University of Texas at Austin, Austin, Texas djohnston@mail.clm.utexas.edu.
authors: Daniel
authors: D
authors: Johnston
mesh_terms: D058916:Adenosine A1 Receptor Antagonists / Q000494:pharmacology; D000818:Animals; D001464:Barium / Q000494:pharmacology; D001514:Bee Venoms / Q000494:pharmacology; D056547:CA1 Region, Hippocampal / Q000502:physiology*; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels / Q000037:antagonists & inhibitors / Q000502:physiology*; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D026902:Potassium Channel Blockers / Q000494:pharmacology; D017966:Pyramidal Cells / Q000502:physiology*; D017207:Rats, Sprague-Dawley; D043682:Receptor, Adenosine A1 / Q000502:physiology*; D014970:Xanthines / Q000494:pharmacology
chemical_list: D058916:Adenosine A1 Receptor Antagonists; D001514:Bee Venoms; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D026902:Potassium Channel Blockers; D043682:Receptor, Adenosine A1; D014970:Xanthines; D001464:Barium; C029738:tertiapin; C051360:1,3-dipropyl-8-cyclopentylxanthine
keywords: A1 adenosine receptors; GIRK; dorsal and ventral hippocampus
references: Eur J Pharmacol. 1993 Jun 24;237(2-3):191-5
references: 8103461
references: J Biol Chem. 2012 May 18;287(21):17656-61
references: 22511771
references: J Neurosci. 1996 Jun 1;16(11):3559-70
references: 8642402
references: Neuron. 2012 Aug 9;75(3):503-16
references: 22884333
references: J Physiol. 2012 Nov 15;590(22):5707-22
references: 22988138
references: J Neurophysiol. 2013 Apr;109(7):1940-53
references: 23324324
references: Biochemistry. 1999 Oct 26;38(43):14294-301
references: 10572004
references: J Neurophysiol. 2001 Feb;85(2):926-37
references: 11160523
references: Nature. 2001 Jun 14;411(6839):805-10
references: 11459060
references: Brain Res. 2002 Sep 6;948(1-2):117-21
references: 12383962
references: Neurosci Lett. 2004 Jan 23;355(1-2):21-4
references: 14729225
references: J Physiol. 1978 Jul;280:169-91
references: 308537
references: Nature. 1978 Dec 21-28;276(5690):839-41
references: 214714
references: Biophys J. 1980 Jun;30(3):473-88
references: 6266531
references: Neurosci Lett. 1983 May 27;37(1):81-5
references: 6308521
references: Science. 1986 Dec 5;234(4781):1261-5
references: 2430334
references: Proc Natl Acad Sci U S A. 1987 Aug;84(15):5487-91
references: 2440052
references: J Physiol. 1987 Sep;390:335-55
references: 2450994
references: J Neurosci. 1988 Nov;8(11):4299-306
references: 2903227
references: Neurosci Lett. 1989 Apr 24;99(1-2):107-12
references: 2748004
references: J Physiol. 1988 Nov;405:677-97
references: 3267155
references: Br J Pharmacol. 1989 Sep;98(1):13-28
references: 2679954
references: J Comp Neurol. 1990 Dec 15;302(3):515-28
references: 1702115
references: J Neurosci. 1991 Dec;11(12):3861-7
references: 1744694
references: J Neurosci. 1996 Mar 15;16(6):1990-2001
references: 8604043
references: Trends Neurosci. 1996 Apr;19(4):150-4
references: 8658599
references: J Neurosci. 1996 Nov 15;16(22):7137-50
references: 8929423
references: Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):923-7
references: 9023358
references: Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):1007-12
references: 9023373
references: Nature. 1997 Jun 26;387(6636):869-75
references: 9202119
references: Neuron. 1997 Sep;19(3):687-95
references: 9331358
references: J Neurosci. 1998 Oct 1;18(19):7613-24
references: 9742133
references: Science. 1998 Dec 4;282(5395):1890-3
references: 9836639
references: Hippocampus. 1998;8(6):608-19
references: 9882018
references: J Okla State Med Assoc. 2004 Dec;97(12):538-42
references: 15732884
references: J Neurosci. 2005 Apr 13;25(15):3787-92
references: 15829630
references: J Neurosci. 2005 Sep 21;25(38):8776-87
references: 16177047
references: Neuropsychopharmacology. 2006 Oct;31(10):2210-20
references: 16407902
references: J Physiol. 2007 May 1;580(Pt.3):787-800
references: 17272353
references: Nat Rev Neurosci. 2008 Mar;9(3):206-21
references: 18270515
references: Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11794-9
references: 19561297
references: Neuron. 2010 Jan 14;65(1):7-19
references: 20152109
references: Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):203-7
references: 21496211
references: J Neurosci. 2012 Mar 14;32(11):3736-47
references: 22423094
references: Pflugers Arch. 1993 Jun;423(5-6):511-8
references: 8351200